Information Provided By:
Fly News Breaks for January 7, 2020
WAT, ILMN, DGX, LH, IQV, CRL, DHR, BRKR, BIO, AVTR, A
Jan 7, 2020 | 16:35 EDT
Wells Fargo analyst Dan Leonard initiated coverage of the Life Science Tools, Services, and Diagnostics Sector in a research note titled "Tools, Services Have Evolved to Better Place but Stay Selective." Leonard said the sectors have "greater secular growth than 5+ years ago, with more exposure to Biopharma and China, and less cyclicality." While the analyst noted the industry has changed for the better, he advocated for being selective, citing elevated relative valuations due to the market recognizing these positives, and decelerating growth. The analyst initiated Agilent (A), Avantor (AVTR), Bio-Rad (BIO), Bruker (BRKR), Danaher (DHR), and Charles River (CRL) with Overweight ratings, noting they were all volatile, and initiated Iqvia (IQV) and LabCorp (LH) with Overweight ratings. The analyst initiated Quest Diagnostics (DGX) and Illumina (ILMN) with Underweight ratings, noting they were both volatile, and also initiated Waters (WAT) with an Underweight rating.
News For A;AVTR;BIO;BRKR;DHR;CRL;IQV;LH;DGX;ILMN;WAT From the Last 2 Days
LH
Mar 28, 2024 | 08:03 EDT
Labcorp (LH) and OPKO Health (OPK) announce that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproductive and women's health across the United States outside of New York and New Jersey. This transaction includes patient service centers and certain customer contracts and operating assets. BioReference Health will continue to offer oncology and urology diagnostic services nationwide, as well as maintain its full operations in New York and New Jersey. When complete, the transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities in key regions across the country. The assets that Labcorp will be acquiring currently generate approximately $100M in annual revenue. The purchase price for the transaction is $237.5M. The proposed acquisition meets Labcorp's strategic and financial criteria. The transaction is subject to customary closing conditions and applicable regulatory approvals, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The transaction is anticipated to close in the second half of 2024.